Tags

Type your tag names separated by a space and hit enter

Ambisome plus miltefosine for Indian patients with kala-azar.
Trans R Soc Trop Med Hyg. 2011 Feb; 105(2):115-7.TR

Abstract

The combination of one intravenous administration of 5mg/kg Ambisome and oral administration of miltefosine, 2.5mg/kg/day for 14 days, was evaluated in 135 Indian patients with kala-azar. The Intent-to-Treat cure rate at 6 months was 124 of the 135 enrolled patients (91.9%: 95% CI = 86-96%), and the per protocol cure rate was 124 of 127 evaluable patients (97.6%: 95% CI = 93-100%). Side effects could be attributed to each drug separately: fevers, rigors and back pain due to Ambisome; gastrointestinal side effects due to miltefosine. This combination is attractive for reasons of efficacy, tolerance, and feasibility of administration, although the gastrointestinal side effects of miltefosine require medical vigilance. Clinical Trials.gov identification number: NCT00371995.

Authors+Show Affiliations

Kala-azar Medical Research Center, Department of Medicine, Institute of Medical Sciences, Banaras Hindu University, Varanasi 221005, India.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

21129762

Citation

Sundar, Shyam, et al. "Ambisome Plus Miltefosine for Indian Patients With Kala-azar." Transactions of the Royal Society of Tropical Medicine and Hygiene, vol. 105, no. 2, 2011, pp. 115-7.
Sundar S, Sinha PK, Verma DK, et al. Ambisome plus miltefosine for Indian patients with kala-azar. Trans R Soc Trop Med Hyg. 2011;105(2):115-7.
Sundar, S., Sinha, P. K., Verma, D. K., Kumar, N., Alam, S., Pandey, K., Kumari, P., Ravidas, V., Chakravarty, J., Verma, N., Berman, J., Ghalib, H., & Arana, B. (2011). Ambisome plus miltefosine for Indian patients with kala-azar. Transactions of the Royal Society of Tropical Medicine and Hygiene, 105(2), 115-7. https://doi.org/10.1016/j.trstmh.2010.10.008
Sundar S, et al. Ambisome Plus Miltefosine for Indian Patients With Kala-azar. Trans R Soc Trop Med Hyg. 2011;105(2):115-7. PubMed PMID: 21129762.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Ambisome plus miltefosine for Indian patients with kala-azar. AU - Sundar,Shyam, AU - Sinha,Prabhat Kumar, AU - Verma,Deepak K, AU - Kumar,Nawin, AU - Alam,Shahnawaj, AU - Pandey,Krishna, AU - Kumari,Poonam, AU - Ravidas,Vidyanand, AU - Chakravarty,Jaya, AU - Verma,Neena, AU - Berman,Jonathan, AU - Ghalib,Hashim, AU - Arana,Byron, Y1 - 2010/12/03/ PY - 2010/05/28/received PY - 2010/10/28/revised PY - 2010/10/28/accepted PY - 2010/12/7/entrez PY - 2010/12/7/pubmed PY - 2011/5/6/medline SP - 115 EP - 7 JF - Transactions of the Royal Society of Tropical Medicine and Hygiene JO - Trans R Soc Trop Med Hyg VL - 105 IS - 2 N2 - The combination of one intravenous administration of 5mg/kg Ambisome and oral administration of miltefosine, 2.5mg/kg/day for 14 days, was evaluated in 135 Indian patients with kala-azar. The Intent-to-Treat cure rate at 6 months was 124 of the 135 enrolled patients (91.9%: 95% CI = 86-96%), and the per protocol cure rate was 124 of 127 evaluable patients (97.6%: 95% CI = 93-100%). Side effects could be attributed to each drug separately: fevers, rigors and back pain due to Ambisome; gastrointestinal side effects due to miltefosine. This combination is attractive for reasons of efficacy, tolerance, and feasibility of administration, although the gastrointestinal side effects of miltefosine require medical vigilance. Clinical Trials.gov identification number: NCT00371995. SN - 1878-3503 UR - https://www.unboundmedicine.com/medline/citation/21129762/Ambisome_plus_miltefosine_for_Indian_patients_with_kala_azar_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0035-9203(10)00238-5 DB - PRIME DP - Unbound Medicine ER -